Skip to main content
20 search results for:

Lenvatinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-08-2023 | Renal cell carcinoma | News | Article

    Potential of pembrolizumab plus lenvatinib for non-clear-cell RCC shown

    The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

  2. 19-10-2021 | EMA | News | Article
    approvalsWatch

    EMA gives green light for first-line use of lenvatinib plus pembrolizumab in advanced RCC

    This decision follows the positive results of the phase 3 CLEAR trial , which showed a significant progression-free and overall survival benefit with use of lenvatinib plus pembrolizumab relative to sunitinib.

  3. 16-08-2021 | FDA | News | Article
    approvalsWatch

    Lenvatinib–pembrolizumab gets FDA nod for first-line advanced RCC

    medwireNews : The US FDA has approved the combination of lenvatinib and pembrolizumab for treatment-naïve adult patients with advanced renal cell carcinoma (RCC).

  4. 09-06-2021 | ASCO 2021 | Conference coverage | Article

    HRQoL data favor lenvatinib–pembrolizumab over sunitinib in advanced RCC

    Patients who receive lenvatinib plus pembrolizumab for advanced renal cell carcinoma report similar or better health-related quality of life than those who receive sunitinib, show data from the phase 3 CLEAR trial.

  5. 23-04-2021 | Renal cell carcinoma | News | Article

    Lenvatinib–everolimus has ‘encouraging activity’ in untreated non-clear cell RCC

    Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.

  6. 16-02-2021 | ASCO GU 2021 | Conference coverage | Article

    Lenvatinib plus pembrolizumab achieve CLEAR survival advantage for clear cell RCC

    The CLEAR study has demonstrated a significant progression-free survival gain with use of lenvatinib plus pembrolizumab for the first-line treatment of advanced clear cell renal cell carcinoma.

  7. 12-06-2020 | ASCO 2020 | Conference coverage | Article

    Second-line lenvatinib–pembrolizumab shows promise for metastatic ccRCC

    Research suggests that patients with metastatic clear cell renal cell carcinoma with disease progression after immune checkpoint inhibitor therapy may benefit from the combination of lenvatinib and pembrolizumab. This independent news story was supported by an educational grant from Pfizer and Merck KGa

  8. 30-01-2020 | Renal cell carcinoma | News | Article

    Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

    Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.

  9. 22-02-2018 | NICE | News | Article
    approvalsWatch

    Cabozantinib, lenvatinib, sorafenib approved for UK thyroid cancer patients

    In addition, the multikinase inhibitors lenvatinib and sorafenib have both been recommended for the treatment of patients with locally advanced or metastatic differentiated thyroid cancers that have continued to progress despite surgery and radioactive iodine therapy.

  10. 19-06-2017 | Lenvatinib | News | Article
    ASCO 2017

    Lenvatinib equals sorafenib for unresectable HCC OS

    REFLECT study findings indicate that lenvatinib offers non-inferior overall survival compared with the current standard of care, sorafenib, for the first-line treatment of patients with unresectable hepatocellular carcinoma.

  11. 14-11-2022 | Renal cell carcinoma | News | Article

    Second-line metastatic RCC outcomes similar regardless of first-line immunotherapy combo partner

    All patients in the dual IO group received nivolumab plus ipilimumab, while the most common regimens in the TKI plus IO group were axitinib plus pembrolizumab (34%), lenvatinib plus pembrolizumab (29%), and axitinib plus avelumab (25%).

  12. 06-08-2021 | Urothelial cancer | Feature | Article
    Updated January 2023

    At a glance: First-line immunotherapy for advanced urothelial carcinoma

    Study details Treatments Primary endpoints Link CheckMate 901 – Phase 3 •    Nivolumab plus ipilimumab; •    Nivolumab plus standard-of-care chemotherapy; or •    Chemotherapy alone   •    OS in cisplatin-ineligible participants; •    OS in participants with ≥1% PD-L1 expression; •    PFS by blinded independent review in cisplatin-eligible participants; and •    OS in cisplatin-eligible participants   https://clinicaltrials.gov/ct2/show/NCT03036098 LEAP-011 – Phase 3 Cisplatin-ineligible patients with PD-L1 CPS ≥10 or platinum-ineligible Pembrolizumab plus lenvatinib; or Pembrolizumab plus placebo PFS by blinded independent review; andOS https://clinicaltrials.gov/ct2/show/NCT03898180 NILE – Phase 3 Durvalumab plus standard-of-care chemotherapy; Durvalumab and tremelimumab plus chemotherapy; or Chemotherapy alone OS https://clinicaltrials.gov/ct2/show/NCT03682068 FIGHT-205 – Phase 2 Cisplatin-ineligible patients whose tumors carry FGFR3 mutations or rearrangements Pemigatinib plus pembrolizumab; Pemigatinib alone; or Standard of care (chemotherapy or pembrolizumab) PFS https://clinicaltrials.gov/ct2/show/NCT04003610 PemCab – Phase 2 Cisplatin-ineligible patients with PD-L1 CPS ≥10 or platinum-ineligible Pembrolizumab plus cabozantinib ORR https://clinicaltrials.gov/ct2/show/NCT03534804 NCT04863885 – Phase 1/2 Cisplatin-ineligible patients Ipilimumab, nivolumab plus sacituzumab govitecan at various doses Maximum tolerated dose; andORR https://clinicaltrials.gov/ct2/show/NCT04863885 medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group This independent article was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  13. 23-05-2022 | Multitargeted kinase inhibitors | News | Article

    Oral retinoid may relieve multikinase inhibitor-related hand–foot skin reaction

    The most common multikinase inhibitor in the cohort was regorafenib, used in four patients, with cabozantinib, lenvatinib, sorafenib, and sunitinib used in one patient each.

  14. 10-05-2021 | Adis Journal Club | Article
    Targeted Oncology

    Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study

    Finally, CVAEs were reported more often following lenvatinib and sunitinib treatment compared to other VEGFR-TKIs.

  15. play
    25-02-2021 | ASCO GU 2021 | Conference coverage | Video

    Clinical insights into renal cell carcinoma trials

    Nazli Dizman shares her highlights of the renal cell carcinoma presentations at the 2021 Genitourinary Cancers Symposium prostate cancer track, including the SWOG 1500 and CLEAR trials.

  16. 25-11-2020 | Tyrosine kinase inhibitors | News | Article

    Bleeding risk doubled during concurrent VEGFR–TKI, anticoagulant therapy

    The patients received one or more VEGFR–TKIs (pazopanib, sunitinib, sorafenib, axitinib, regorafenib, vandetanib, lenvatinib, or cabozantinib) and factor Xa inhibitors (low molecular weight heparin [LMWH] including enoxaparin or the direct oral anticoagulants [DOACs] rivaroxaban or apixaban) between 2010 and 2018 whilst undergoing treatment for a variety of cancers, including renal cell carcinoma (48.8%), sarcoma (23.3%), and colorectal cancer (11.6%).

  17. play
    04-06-2020 | ASCO 2020 | Conference coverage | Video

    Researcher comment: The KEYNOTE-146/Study 111 trial

    Chung-Han Lee reports the final analysis of KEYNOTE-146/Study 111 trial of lenvatinib plus pembrolizumab in metastatic clear-cell renal cell carcinoma after immune checkpoint inhibitor therapy (4:57). This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

  18. 22-08-2018 | FDA | News | Article
    approvalsWatch

    FDA announces approvals for metastatic SCLC, unresectable HCC

    . --- The FDA has also given the nod to the multikinase inhibitor lenvatinib for the treatment of patients with newly diagnosed, inoperable HCC.

  19. 08-08-2017 | Non-small-cell lung cancer | At a glance | Article
    Updated July 2019

    At a glance: The KEYNOTE lung cancer trials

    All participants will receive pembrolizumab plus either lenvatinib, or the anti-LAG3 monoclonal antibodies MK-4280 or MK-1308.

  20. 04-08-2016 | Renal cell carcinoma | Article

    Medical treatment of renal cancer: new horizons

    Patients were randomised to lenvatinib, everolimus or a combination of both drugs.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.